Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.
Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AMLAugust 31st 2022
In an interview with Targeted Oncology, Eunice S. Wang, MD, discussed the growing use of menin inhibitors in acute myeloid leukemia, and clinical trial research further supporting the treatment strategy.
Behind the FDA Approval: Pemigatinib for R/R Myeloid/Lymphoid NeoplasmsAugust 30th 2022
In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.
Doctors Debate: Should Systemic Therapy for UTUC Be Given in the Adjuvant or Neoadjuvant Setting?August 25th 2022
During the 2022 Debates and Didactics in Hematology and Oncology conference, Bassel Nazha, MD, MPH and Jacqueline T. Brown, MD, debated on adjuvant vs neoadjuvant systemic therapy for patients with upper tract urothelial cancer.
NGS Testing May Be Better Than Single-Gene Testing for Identifying Mutations in NSCLCAugust 18th 2022
In an interview with Targeted Oncology, Brandon Sheffield, MD, discussed relevant biomarkers for testing in patients with non–small cell lung cancer, and the cost-effectiveness of single-gene test vs next-generation sequencing.
Optimal Precision Medicine Practices Not Commonly Performed for Medicaid Beneficiaries With NSCLCAugust 17th 2022
In an interview with Targeted Oncology, Cary Gross, MD, discussed retrospective research that revealed testing and treatment disparities among Medicaid beneficiaries with advanced non–small cell lung cancer, and the steps needed to improve outcomes for the patient population.
FDA Accepts sBLA for Polatuzumab Vedotin Combination in Previously Untreated DLBCLAugust 16th 2022
By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.
Trastuzumab Deruxtecan Shows Survival Improvement in HER2-positive Metastatic Breast CancerAugust 15th 2022
Findings from the phase 2 DESTINY-Breast02 show that trastuzumab deruxtecan improves both progression-free and overall survival in patients with HER2-positive unresectable and/or metastatic breast cancer.
FDA Grants Regular Approval to Capmatinib for Patients With METex14-Positive NSCLCAugust 11th 2022
An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.
FDA Grants Priority Review to NDA for Elacestrant in ER+/HER2- Advanced or mBCAugust 11th 2022
Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review.
HRQOL Disparities Identified in Older Patients Living in Rural CommunitiesAugust 11th 2022
In an interview with Targeted Oncology, Jennifer Moss, MD, discussed health-related quality-of-life in older, rural vs urban patients with cancer and survivors. She also explained factors contributing to the disparity and how to improve outcomes for the population.
Ide-cel Prolongs Progression-Free Survival in Heavily Pretreated R/R Multiple MyelomaAugust 10th 2022
Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.
Subcutaneous Atezolizumab Non-Inferior to IV Formulation in Locally Advanced or Metastatic NSCLCAugust 2nd 2022
In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.
Study of Monalizumab and Cetuximab in Recurrent/Metastatic SCCHN DiscontinuedAugust 1st 2022
The phase 3 INTERLINK-1 study of monalizumab and cetuximab as treatment of recurrent or metastatic squamous cell carcinoma of the head and neck has been discontinued. The study did not meet its efficacy goal.